Small-Molecule APIs

Sep 18, 2018
By Pharmaceutical Technology Editors
The $425-million acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.
Sep 04, 2018
By Pharmaceutical Technology Editors
As it investigates the root cause of an impurity discovered in valsartan, FDA extends its studies to APIs with similar synthesis processes.
Jul 23, 2018
By Pharmaceutical Technology Editors
The acquisition will place Cambrex into the finished dosage form CDMO market.
May 16, 2018
By Pharmaceutical Technology Editors
Cambrex Corporation has announced facility, equipment, and instrument upgrades at its High Point, NC facility and updated progress on expansions in Cedar City, IA.
Apr 24, 2018
By Pharmaceutical Technology Editors
Porton will use biocatalyst technologies from Codexis to accelerate API development for clients.
Apr 20, 2018
By Pharmaceutical Technology Editors
The contract renewal allows AMRI to continue to provide medicinal chemistry and ADME services for advancing drug discovery programs in neurotherapeutics.
Mar 02, 2018
Pharmaceutical Technology
Assessing potential formulation and manufacturing issues in early development phases can improve a drug’s chances for success.
Feb 01, 2018
By Pharmaceutical Technology Editors
Avista Pharma's strengthens early phase drug development offerings with acquisition of Solid Form Solutions.
Feb 01, 2018
By Pharmaceutical Technology Editors
Cambrex invests in development and laboratory facilities and adds staff.
Jan 16, 2018
By Pharmaceutical Technology Editors
A ceremony was held at Cambrex’s Karlskoga facility to mark the commencement of a long-term manufacturing agreement with AstraZeneca for a key intermediate.
native1_300x100
lorem ipsum